Case | Age | Sex | Disease | ICI Therapy | Time to Presentation from ICI Initiation | Baseline Medical History |
---|---|---|---|---|---|---|
1 | 70 | Male | Melanoma | Ipilimumab/Nivolumab | 11 Days | Hypertension Colon Cancer |
2 | 79 | Male | Melanoma | Pembrolizumab | 26 Days | CLL |
3 | 61 | Female | Breast Cancer | Durvalumab/Tremelimumab | 28 Days | None |
4 | 69 | Male | Urothelial Carcinoma | Pembrolizumab | 132 Days | CKD, Hypertension, Hyperlipidemia |
Type 2 DM | ||||||
CAD | ||||||
5 | 67 | Female | Melanoma | Ipilimumab/Nivolumab | 14 Days | None |
6 | 83 | Male | Melanoma | Nivolumab, Adjuvant | 31 Days | Hypertension, |
Hyperlipidemia | ||||||
Atrial fibrillation | ||||||
7 | 70 | Male | Renal Cell Carcinoma | Ipilimumab/Nivolumab | 21 Days | Hypertension, CKD, Atrial Fibrillation |
8 | 89 | Male | Non-Small Cell Lung Carcinoma | Pembrolizumab | 32 Days | Hypertension, Hyperlipidemia, CAD, CKD, Type 2 DM |